Gilead pays partner Hookipa $10M for HBV, HIV vaccines
|
Gilead is paying $10 million for sole ownership of
arenaviral immunotherapies for hepatitis B and HIV. |
HIV pill improves diabetic eye disease without injections
An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study suggests. View article...